

第26屆國家磐石獎

The 26th National Award of
Outstanding SMEs



科懋生物科技股份有限公司

EXCELSIOR BIOPHARMA INC.



董事長 陳澤民先生
Chairman : Mr. Joseph Chen

負責人：陳澤民

地址：11503台北市南港區園區街3號14樓之6

電話：02-26557568

傳真：02-26557915

推薦單位：玉山商業銀行

營業項目：處方用藥、指示用藥、保健產品、快速檢驗試劑、生技醫藥產品、技術服務之研發、生產和銷售

產品名稱：罕見疾病藥物、解毒劑、特殊癌症藥物、艾快定®快速檢驗試劑、脂妙清®、歐三加福®魚油、芮芙荳®護益膚和玫瑰果油系列、AB益生菌系列產品、蓋抹滅®醫藥級活性碳膠囊、口立淨7®口腔保健酵素牙膏漱口水和口腔凝膠



<http://www.excelsiorgroup.com.tw>

Owner : Joseph Chen

Address : 14F-6, No. 3, Park Street, Nangang District, Taipei, Taiwan, R.O.C

Tel : +886-2-26557568

Fax : +886-2-26557915

Recommended by :

E. Sun Commercial Bank

Business Items :

Research, production and distribution of prescription only medicine, general pharmaceuticals, monoclonal antibody rapid tests, food supplements, and medical devices.

Products :

Orphan drugs, antidotes, Actim® rapid tests, Omacor®, Om3gafort® EPA, Om3gafort® DHA, Atopic piel®, Repavar®, AB-Life®, AB-I3.1®, AB-Kolicare®, Norit® Capsules, Oral7® Mouth Hygiene Products



產品 Product



脂妙清®軟膠囊1000毫克
Omacor® Soft Capsules
1000mg



公司總部 Headquarter



科懋生物科技股份有限公司
EXCELSIOR BIOPHARMA INC.



生產作業情形 Production line



研發部門 R&D

科懋生技創立於1988年，初期以藥品代理進口和國內銷售為主，歷經1995年全民健保實施後醫療藥品市場迅速成長的時代，見證了近30年來，台灣廠商在醫藥發展史上點點滴滴辛苦的付出和經營的成果。

專業、創新、卓越、服務

基於「特殊醫療」領域之專業，以及「社會關懷、人道服務」之精神，在國內罕見疾病（意指罹患率極低、患者人數極少的疾病）患者以及醫師的努力下，科懋生技共同參與催生2000年2月9日公告和實施之《罕見疾病防治及藥物法》，在當時台灣是全世界第五個立法保障罕見疾病患者與家屬的國家。

同年，衛生福利部指導「榮總毒藥物防治

諮詢中心」及國內各大醫院共同建構「全國解毒劑儲備網」，科懋生技協助多項專用解毒劑的供應及儲備，並積極推廣醫院及特定企業自主儲備必要解毒劑，提升緊急應變災害之急救醫療所需。

科懋生技自1998年開始從事罕見疾病藥物的研發和生產製造，持續配合政府單位及社會機構，舉辦研討會及支持病友會等服務工作，提供藥物資訊及治療管道的醫療諮詢服務，建立醫療社群對疾病的認知，協助患者獲得適當醫療照護，以改善病患之生活品質。



舉辦第一屆轉化生長因子國際學術研討會
The 1st international symposium on TGF- β and Disease



生產作業情形 Production line

這些年來，也有賴於衛生福利部持續推動罕見疾病醫療和健康照護的支持和健保給付，罕見疾病家庭才能在面臨人生低潮困窘之際，得到片刻喘息及希望曙光。

在地深耕 行銷亞洲各國

由於特殊醫療藥品市場有限，藥廠投入研發及生產的成本極高，因而降低藥品開發及生產之意願，也影響到市場供給，為能有效生產及供應國內外患者所需，科懋生技透過投資成立子公司科進製藥，1996年進駐工研院創業育成中心進行新藥研發，繼而興建符合PIC/S GMP國際標準的藥廠和新藥研發中心，專注開發適合台灣和亞洲國家之罕見疾病治療藥物，藉以有效掌握關鍵生產技術，並培植台灣新藥研發和專業醫療服務人才，同時作為研發新藥和營運佈局亞太市場之基礎。

近年完成國內臨床試驗取得之新成分新藥許可證「脂妙清®軟膠囊OMACOR® Soft Capsules」已成功上市之外，另透過產學合作計畫，將EX039藥品應用於治療輕度阿茲海默氏症之新適應症研究，新藥研發上的堅持，也讓我們公司持續在醫療領域中貢獻心力。



卓越事蹟：藥物科技研究發展獎暨罕見疾病藥物供應製造及研究發展獎
National Awards of Orphan Drug Production and Research Development Contribution on Rare Diseases by Department of Health

超越巔峰 追求卓越與社會關懷的經營理念

陳董事長秉持「超越巔峰、追求卓越」之信念，健全完善組織、保險及福利制度，提供員工安全與公平之工作機會，建立員工持續教育訓練及人才培育計畫，讓同仁在專業職涯中持續不斷地精進創新、追求卓越和超越巔峰，同時引領全體同仁投入社會關懷人道服務，並將公司週年紀念日訂為志工服務日，當日所有同仁放下工作，走向需要幫助的地方，捲起衣袖投入志工服務之行列，落實回饋和服務社會之企業社會責任。

一起點亮生命的色彩

由於我國罕見疾病定義相較歐美日各國侷限，故在醫療上仍有一些特殊疾病，如非遺傳性罕見疾病、特殊疾病用藥等，尚無法得到健保給付而失去救命之契機，面對種種的困境，陳董事長期許同仁能夠持續努力，為這些病患盡一份心力，使他們的人生也能夠如同我們一樣，享受生命的光彩和榮耀。▲



教育訓練 Employee training

Excelsior Biopharma Inc. was founded in 1988, and in the early stages we imported and marketed pharmaceuticals in Taiwan as a local distributor. After the implementation of the National Health Insurance in 1995, the era of rapid growth of the pharmaceutical market, we also witnessed the contribution and fruitful outcome devoted by pharmaceutical manufacturers and dealers in the history of medical and pharmaceutical development during the past three decades in Taiwan.

“Professionalism, Innovation, Excellence, Service”

Based on the professionalism in the field of "specialty healthcare" and the spirit of "social care with humanitarian service", Excelsior Biopharma, rare disease patients and physicians jointly participated in the legislature of the "Prevention of Rare Diseases and Orphan Drug Act" practiced on February 9, 2000. At that time, Taiwan was the world's fifth country to legislate acts to protect rare disease patients and their families.

In the same year, Excelsior Biopharma assisted the "National Taiwan Poison Center" under the national budget by the Ministry of Health and Welfare to build up the "National Antidote Distribution Network". Excelsior Biopharma was responsible for the storage and supply of several specific antidotes and actively promoted the awareness and necessity of hospitals and enterprises to prepare essential and specific antidotes to enhance emergency medical care.

Excelsior has been engaged in the development and manufacturing of orphan drugs since 1998. We have continued to collaborate closely with relevant government agencies and social institutions to



舉辦第一屆轉化生長因子國際學術研討會
The 1st international symposium on TGF- β and Disease

provide drug information and medical consultation through seminars and support activities to patient advocacy groups to increase disease awareness in the medical community, to help patients receive the appropriate healthcare and medication, and to improve their quality of life.

Over the years, relying on the Ministry of Health and Welfare to continue to provide medical support and healthcare, such as the national health insurance reimbursement system for rare disease patients, their families could be relieved from the financial burden and light up hope in their difficult lives.

Enforce medical examination, new drug research, local production, and professional medical service in Taiwan, and provide orphan drugs and share medical experience to Asian countries

Due to the limited market potential of specialty medicine, the costs of R&D and production of orphan drugs is extremely high. Thus, it reduces the willingness for drug development and production. It also affects the supply of orphan drugs to the market. The company invested in and founded its subsidiary, Excelsior Pharmatech Labs. in the Incubation Center of ITRI in 1996, and established a new pharmaceutical manufacturing plant with PIC/S GMP international standards and new drug research centers, specializing in specialty medicines for Taiwan and Asian countries in Hsinchu Biomedical Science Park. It can effectively produce and supply orphan drugs to



科懋30周年慶愛心園遊會 Excelsior 30th anniversary and charity carnival

Taiwan and other Asian markets. The company keeps key production technology, talented R&D know-how, and professional medical service personnel, and medical examination tools are cultivated as the core competence for the rare diseases and specialty medicines in Asia-Pacific markets.

After completion of local clinical trials in recent years, Excelsior obtained a new drug (NCE) license "OMACOR®" which has been successfully marketed since July 2016. There are several ongoing investigations to expand new indications of EX039 in the treatment of mild Alzheimer's disease. Through the expansion in R&D activities, the company continues making contributions to the treatment of neuropsychiatric diseases, besides the rare diseases.

The pursuit of excellence, beyond the peak and the business philosophy of social care

Mr. Joseph Chen, president of Excelsior group, holds to "the pursuit of excellence and beyond the peak", and is committed to improving the organization; insurance and welfare system; providing employees with safe and fair job opportunities; establishing staff education and personnel training programs so that all colleagues can pursue excellence, and continuous innovation; and surpass the peak in their career. To implement corporate social responsibility and lead employees to invest in social care service in the company, the annual anniversary of Excelsior has been appointed as a volunteer service day for several years. Mr. Chen leads all staff in their devotion to social care, with all of us put down the work of the day, to where the community needs to help, and roll up our sleeves to offer volunteer services every year.

Together, light up their lives

As the definition of rare disease in Taiwan is very limited compared to Europe, the United States and Japan, such as non-hereditary rare diseases, specialty medicines may be excluded from national health insurance programs. So, there are still some patients who could not receive the appropriate life-saving treatments due to the lack of reimbursement. Therefore, Mr. Chen expects all colleagues to be able to concentrate their efforts for these patients, to light up their lives and enjoy the glory and happiness of life as we do. ▴

綜合評語 Commentary

以特殊醫療為主軸，建立自我品牌與技術，專業評估掌握供需結構和市場狀況，透過多元且深入的醫療銷售通路，積極拓展亞洲罕見疾病用藥市場。熱心社會公益，提供特殊醫療照護，協助政府建立「全國解毒劑儲備網」，值得肯定。

Dedicated to special medical supplies, and well established with its own brands and technologies, this company keeps abreast of market structures and market outlooks from a professional perspective. Through in-depth and diversified marketing channels, this company proactively develops the market of orphan drugs for rare diseases in Asia. Nonetheless, this company is making every efforts in social charity and provides special medical attention and care in helping the government build up the "National Antidote Distribution Network" which should be applauded.